What is the recommended dosing for rizatriptan (triptan) in patients with migraine with aura?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 10, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Rizatriptan Dosing for Migraine with Aura

For migraine with aura, rizatriptan should be dosed at 5-10 mg orally every two hours as needed, with a maximum daily dose of 30 mg in any 24-hour period. 1

Recommended Dosing Protocol

  • The recommended starting dose of rizatriptan is either 5 mg or 10 mg for acute treatment of migraine attacks, including those with aura 1
  • The 10 mg dose may provide greater effectiveness than the 5 mg dose but carries a higher risk of adverse reactions 1, 2
  • If migraine headache returns after initial treatment, a second dose may be administered 2 hours after the first dose 1
  • Do not exceed 30 mg in any 24-hour period 1
  • The safety of treating more than four headaches in a 30-day period has not been established 1

Special Dosing Considerations

Patients Taking Propranolol

  • For patients taking propranolol, only the 5 mg dose of rizatriptan is recommended 1
  • Maximum of 3 doses (15 mg total) in any 24-hour period for adults on propranolol 1

Pediatric Dosing

  • For patients 6-17 years: 5 mg for those weighing less than 40 kg (88 lb) 1
  • For patients 6-17 years: 10 mg for those weighing 40 kg (88 lb) or more 1
  • For pediatric patients on propranolol weighing ≥40 kg: only a single 5 mg dose is recommended 1
  • Rizatriptan should not be prescribed to propranolol-treated pediatric patients who weigh less than 40 kg 1

Timing of Administration

  • Triptans are most effective when taken early in an attack, when the headache is still mild 3
  • However, triptans should not be administered during the aura phase of a migraine attack 3
  • Wait until the aura symptoms have resolved and the headache phase has begun before administering rizatriptan 3

Efficacy and Comparative Performance

  • Rizatriptan has an efficacy rating of 4 out of 4 (highest effectiveness) for migraine treatment 3
  • At 2 hours after dosing, up to 77% of patients taking rizatriptan 10 mg experience pain relief compared with 37% of those taking placebo 2
  • Up to 44% of patients are completely pain-free at 2 hours compared with 7% of those taking placebo 2
  • Rizatriptan 10 mg provides faster pain relief and higher percentage of patients with absence of pain than naratriptan 2.5 mg or zolmitriptan 2.5 mg 4

Contraindications and Precautions

  • Rizatriptan should not be used with ergot-type medications, other triptans, MAOIs, or in patients with CAD 3
  • Triptans are contraindicated in patients with:
    • Uncontrolled hypertension 3
    • Basilar or hemiplegic migraine 3
    • Ischemic vascular conditions 5
    • Vasospastic coronary disease 5
    • Significant cardiovascular disease 5

Common Side Effects

  • Most common side effects (incidence >2%) are typically transitory (2-3 hours) and mild to moderate 2
  • Side effects may include:
    • Tachycardia or bradycardia 3
    • Throat tightness 3
    • Dizziness, somnolence, asthenia/fatigue, and nausea 6
    • Chest pressure or heaviness and paresthesias 5

Clinical Pearls

  • If a patient experiences unpleasant sensory disturbances with rizatriptan, trying a different triptan may be beneficial 5
  • Patients should try rizatriptan for 2-3 headache episodes before abandoning this therapy 5
  • For patients who experience relapse (return of symptoms within 48 hours), rizatriptan can be repeated or combined with fast-acting NSAIDs like naproxen sodium, ibuprofen lysine, or diclofenac potassium 3
  • Be aware that repeated treatment does not preclude further relapses and ultimately increases the risk of medication overuse headache 3

References

Research

Rizatriptan in the treatment of migraine.

Clinical therapeutics, 1999

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Triptans and Sensory Disturbances

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.